Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Local Stocks
Stocks of Local Interest
PG Energy Index
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
(NQ:
)
N/A
UNCHANGED
Last Price
Updated:
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about
< Previous
1
2
Next >
Cytori Therapeutics Reminds Investors of Today’s Deadline to be a Shareholder of Record
June 22, 2018
Cytori Therapeutics, Inc. (NASDAQ:CYTX) (“Cytori” or the “Company”) today issued a reminder to shareholders that the Record Date of its proposed rights offering is June 26, 2018. To be a shareholder of...
From
GlobeNewswire News Releases
The Stem Cell Market is Projected to Grow Due to Technological Advancements
May 31, 2018
FinancialBuzz.com News Commentary
From
PR Newswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Cytori Therapeutics, Inc.
May 18, 2018
Levi & Korsinsky announces it has commenced an investigation of Cytori Therapeutics, Inc.
From
Business Wire News Releases
Cytori Reports Q1 2018 Business and Financial Results
May 10, 2018
Cytori Therapeutics (NASDAQ:CYTX) (“Cytori” or the “Company”) today announced Q1 2018 financial results and provided updates on corporate development.
From
GlobeNewswire News Releases
Cytori to Webcast First Quarter Financial Results on May 10
May 07, 2018
Cytori Therapeutics, Inc. (NASDAQ:CYTX) will provide a live webcast of its first quarter financial results and business update on Thursday, May 10, 2018 at 5:30 PM Eastern Time.
From
GlobeNewswire News Releases
Cytori Provides Update on US Manufacturing and EU Approval Plans for ATI-0918, Liposomal Doxorubicin
April 30, 2018
Cytori Therapeutics, Inc. (Nasdaq:CYTX) (“Cytori” or “the Company”) today provided an update on its plans for US manufacturing and EU approval for its ATI-0918 liposomal doxorubicin product. ATI-0918...
From
GlobeNewswire News Releases
Enrollment Completed in ADRESU Clinical Trial of Cytori Cell Therapy™ for Stress Urinary Incontinence
March 28, 2018
Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced today that full enrollment has been reached in the ADRESU investigator-initiated clinical trial of Cytori Cell Therapy™ for men with stress urinary...
From
GlobeNewswire News Releases
Cytori Reports Fourth Quarter and Full Year 2017 Business and Financial Results
March 08, 2018
Cytori Therapeutics (NASDAQ:CYTX) (“Cytori” or the “Company”) today announced its fourth quarter and year-end 2017 financial results and provided updates on its corporate activity and clinical...
From
GlobeNewswire News Releases
Cytori to Webcast Fourth Quarter Financial Results on March 8th
February 22, 2018
Cytori Therapeutics, Inc. (NASDAQ:CYTX) will provide a live webcast of its fourth quarter financial results and business update on Thursday, March 8, 2018 at 5:30 PM Eastern Time.
From
GlobeNewswire News Releases
Cytori Scleroderma Trial Data Presented at Systemic Sclerosis World Congress
February 15, 2018
Cytori Therapeutics, Inc. (Nasdaq:CYTX) (“Cytori” or “the Company”) today presented data from the U.S. 88 patient, 19 center, randomized, double blind, placebo-controlled STAR clinical trial of Cytori...
From
GlobeNewswire News Releases
Cytori Therapeutics Announces Inducement Grants for New Employees
February 09, 2018
Cytori Therapeutics, Inc. (NASDAQ:CYTX) (the “Company”), announced today that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options on January 25, 2018 to...
From
GlobeNewswire News Releases
Enrollment Completed in Randomized Clinical Trial of Habeo™ Cell Therapy for Scleroderma and Impaired Hand Function
January 22, 2018
Cytori Therapeutics, Inc. (NASDAQ:CYTX) announces completion of patient enrollment in SCLERADEC II (NCT02558543), a randomized, double-blind, placebo-controlled, parallel group, multi-center clinical...
From
GlobeNewswire News Releases
Cytori Closes Rights Offering for Gross Proceeds of $10 Million
November 28, 2017
Cytori Therapeutics, Inc. (“Cytori”) (NASDAQ:CYTX) announced today the closing of its rights offering (the “Rights Offering”) to subscribe for units at a subscription price of $1,000 per unit.
From
GlobeNewswire News Releases
Cytori Announces Expiration of Oversubscribed Rights Offering
November 24, 2017
Cytori Therapeutics, Inc. (NASDAQ:CYTX) ("Cytori" or the "Company"), announced today that the subscription period for its previously announced rights offering (the “Offering”) of units at a...
From
GlobeNewswire News Releases
Cytori Reports Reduction in Fibrosis Parameters in Scar Study
November 20, 2017
BARDA Funded Preclinical Published in Stem Cell Research and Therapy
From
GlobeNewswire News Releases
Cytori Reports Bioequivalence Trial Results in Ovarian Cancer at AAPS
November 16, 2017
Cytori Therapeutics (NASDAQ:CYTX) (“Cytori” or the “Company”) today announced the results of its pharmacokinetic bioequivalence trial of ATI-0918 (test product) and European sourced CAELYX® (reference...
From
GlobeNewswire News Releases
Cytori Reminds Stockholders That Rights Offering Expires on Tuesday, November 21
November 15, 2017
Cytori Therapeutics, Inc. (Nasdaq:CYTX) provides a reminder to stockholders that its previously announced rights offering will remain open until 5:00 PM Eastern Time on Tuesday, November 21, 2017....
From
GlobeNewswire News Releases
Cytori Announces New U.S. Investigator Trial for Hip Osteonecrosis
November 13, 2017
Updates on Other Selected Global Investigator Initiated Trials
From
GlobeNewswire News Releases
Cytori Reports Third Quarter 2017 Business and Financial Results
November 09, 2017
Cytori Therapeutics (NASDAQ:CYTX) (“Cytori” or the “Company”) today announced its third quarter 2017 financial results and provided updates on its corporate activity and clinical development.
From
GlobeNewswire News Releases
STAR Trial Data Accepted for Presentation at Systemic Sclerosis World Congress
November 07, 2017
Cytori Therapeutics, Inc. (Nasdaq:CYTX) (“Cytori” or “the Company”) announced today that its U.S. STAR clinical trial assessing the safety and efficacy of Habeo™ Cell Therapy for hand dysfunction due...
From
GlobeNewswire News Releases
Breakfast Technical Briefing on Biotech Stocks -- Cytori Therapeutics, Sorrento Therapeutics, Marinus Pharma, and NewLink Genetics
November 06, 2017
If you want a Stock Review on CYTX, SRNE, MRNS, or NLNK then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. For today, DailyStockTracker.com observes...
From
PR Newswire
Cytori to Webcast Third Quarter Financial Results on November 9
November 02, 2017
Cytori Therapeutics, Inc. (NASDAQ:CYTX) will provide a live webcast of its third quarter financial results and business update on Thursday, November 9, 2017 at 5:30 PM Eastern Time.
From
GlobeNewswire News Releases
Technical Insights on Biotech Stocks -- Cymabay Therapeutics, Cytori Therapeutics, CytRx, and Sorrento Therapeutics
October 02, 2017
From
PR Newswire
Cytori Announces Corporate Restructuring & Cost Reduction Plan
September 01, 2017
Cytori Therapeutics (NASDAQ:CYTX) (“Cytori” or the “Company”) today announced a substantial corporate restructuring intended to significantly reduce expenses while maintaining its ability to execute on...
From
GlobeNewswire News Releases
Cytori Reports Second Quarter 2017 Business and Financial Results
August 10, 2017
Cytori Therapeutics (NASDAQ:CYTX) (“Cytori” or the “Company”) today announced its second quarter 2017 financial results and provided updates on its corporate activity and clinical development.
From
GlobeNewswire News Releases
Cytori to Webcast Second Quarter Financial Results on August 10
August 04, 2017
Cytori Therapeutics, Inc. (NASDAQ:CYTX) will provide a live webcast of its second quarter financial results and business update on Thursday, August 10, 2017 at 5:30 PM Eastern Time.
From
GlobeNewswire News Releases
The Big Deal About Stem Cell Therapies and Regenerative Medicine
July 28, 2017
Microcapspeculators.com News Commentary
From
PR Newswire
Cytori Therapeutics Announces Inducement Grants for New Employees
July 25, 2017
Cytori Therapeutics, Inc. (NASDAQ:CYTX) (the “Company”), announced today that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options on July 19, 2017 to four...
From
GlobeNewswire News Releases
Cytori Announces Top-Line 24- and 48-Week Results from the STAR Trial of Habeo™ Cell Therapy in Patients with Scleroderma
July 24, 2017
Cytori Therapeutics, Inc. (NASDAQ:CYTX) today announced top-line, preliminary data from its pivotal STAR trial of HabeoTM Cell Therapy in patients with scleroderma. While the primary endpoint, Cochin...
From
GlobeNewswire News Releases
American Medical Association Approves New Category III CPT Codes Describing Cytori’s Scleroderma Therapy
July 10, 2017
Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced today that the American Medical Association’s (AMA) CPT® (Current Procedural Terminology) Editorial Panel has approved the company’s request to add two...
From
GlobeNewswire News Releases
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.